Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 3/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PRLHR | P49683 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847251 | 0.95 | MAPT (0.46) | MAPTGPR119BRD4CREBBPMTOR | |
| SCHEMBL2846204 | 0.91 | CREBBP (0.43) | GPR119BRD4CREBBPTRPV1PRLHR | |
| SCHEMBL2449444 | 0.86 | CREBBP (0.53) | BRD4CREBBPTRPV1PRLHR | |
| SCHEMBL2452090 | 0.86 | CREBBP (0.45) | BRD4CREBBPTRPV1PRLHR | |
| SCHEMBL2846080 | 0.86 | MAPT (0.49) | MAPTGPR119BRD4CREBBPMTOR | |
| SCHEMBL2451416 | 0.83 | MAPT (0.51) | MAPTGPR119BRD4CREBBPMTOR | |
| SCHEMBL2847567 | 0.81 | MAPT (0.43) | MAPTGPR119BRD4CREBBPMTOR | |
| SCHEMBL2846737 | 0.80 | MAPT (0.47) | MAPTGPR119BRD4CREBBPMTOR | |
| SCHEMBL2447065 | 0.78 | MAPT (0.45) | MAPTGPR119BRD4CREBBPMTOR | |
| SCHEMBL2844520 | 0.76 | MAPT (0.42) | MAPTGPR119BRD4CREBBPMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| WO-2010053438-A1 | MODULATORS OF AMYLOID BETA. | ASTRAZENECA AB (SE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130495-A1 | COMPOUNDS 563 | BACE1, PSEN1, PSEN2 | MAPT 10/4885GPR119 1378/4885BRD4 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.